Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 2:38 am
Author: Getaka|Social: XLinkedIn

Astec Lifesciences Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹1,031.32Undervalued by 84.82%vs CMP ₹558.00

P/E (15.0) × ROE (45.3%) × BV (₹186.00) × DY (2.00%)

Defaults: P/E=15

₹408.16Overvalued by 26.85%vs CMP ₹558.00
MoS: -36.7% (Negative)Confidence: 44/100 (Low)Models: 1 Under, 3 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹428.1839%Over (-23.3%)
Net Asset ValueAssets₹185.8524%Over (-66.7%)
ROCE CapitalReturns₹771.3220%Under (+38.2%)
Revenue MultipleRevenue₹256.5518%Over (-54%)
Consensus (4 models)₹408.16100%Overvalued
Key Drivers: EPS CAGR -58.5% drags value — could be higher if earnings stabilize. | Wide model spread (₹186–₹771) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -58.5% · Defaults: P/E=15

*Investments are subject to market risks

Investment Snapshot

56
Astec Lifesciences Ltd scores 56/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health66/100 · Strong
ROCE 12.9% GoodROE 45.3% ExcellentD/E 0.60 ModerateInterest Coverage 0.0x RiskyProfitable 3/5 years Mixed
Smart Money40/100 · Moderate
FII holding stable No changeDII holding down 1.17% MF sellingPromoter holding at 72.0% Stable
Earnings Quality50/100 · Moderate
OPM contracting (18% → -9%) DecliningWorking capital: -26 days (improving) Efficient
Quarterly Momentum60/100 · Moderate
Revenue (4Q): -1% YoY FlatOPM: 3.0% (up 9.0% YoY) Margin expansion
Industry Rank50/100 · Moderate
ROCE 12.9% vs industry 15.2% AverageROE 45.3% vs industry 19.9% Above peers3Y sales CAGR: -17% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 2:38 am

Market Cap 1,243 Cr.
Current Price 558
Intrinsic Value₹408.16
High / Low 991/512
Stock P/E
Book Value 186
Dividend Yield0.00 %
ROCE12.9 %
ROE45.3 %
Face Value 10.0
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Astec Lifesciences Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Astec Lifesciences Ltd 1,243 Cr. 558 991/512 1860.00 %12.9 %45.3 % 10.0
Punjab Chemicals & Crop Protection Ltd 1,138 Cr. 928 1,666/80417.8 3260.32 %15.3 %12.0 % 10.0
Excel Industries Ltd 1,109 Cr. 882 1,440/80014.6 1,4381.56 %7.11 %5.21 % 5.00
Meghmani Organics Ltd 1,076 Cr. 42.3 106/36.426.6 60.60.00 %3.39 %0.80 % 1.00
3B Blackbio DX Ltd 991 Cr. 1,154 2,020/1,12017.2 3470.35 %25.8 %19.4 % 10.0
Industry Average9,472.25 Cr1,009.7725.27369.000.53%15.21%19.87%6.67

All Competitor Stocks of Astec Lifesciences Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 117127143111511546999941209174125
Expenses 1051221401146914111611810011410280121
Operating Profit 1253-3-1813-46-20-66-11-74
OPM % 10%4%2%-3%-36%8%-67%-20%-6%5%-12%-9%3%
Other Income 432112122111-1
Interest 6666677910101187
Depreciation 9899999111112111011
Profit before tax 1-6-11-18-32-1-62-39-25-16-33-24-16
Tax % 31%-20%-26%-24%-24%4%-36%0%61%3%0%0%0%
Net Profit 1-5-8-13-24-1-40-39-40-16-33-24-16
EPS in Rs 0.38-2.22-3.66-6.00-10.86-0.43-17.73-17.21-18.03-7.18-14.75-10.96-7.05

Last Updated: February 6, 2026, 3:46 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 20, 2026, 4:00 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 207267233299368431523555677628458381409
Expenses 171213201236299354437443522551464448417
Operating Profit 3554326369768511215477-6-66-8
OPM % 17%20%14%21%19%18%16%20%23%12%-1%-17%-2%
Other Income -0-164-812111281013661
Interest 91313121112135921253737
Depreciation 15131014151923263434364445
Profit before tax 111312295656618912135-62-141-89
Tax % 22%-17%59%33%37%36%23%27%26%27%-24%-4%
Net Profit 915519353648659026-47-135-89
EPS in Rs 4.096.662.248.5715.6516.0321.2129.0440.1211.41-20.95-60.16-39.94
Dividend Payout % 21%16%0%15%8%8%6%5%3%12%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)66.67%-66.67%280.00%84.21%2.86%33.33%35.42%38.46%-71.11%-280.77%-187.23%
Change in YoY Net Profit Growth (%)0.00%-133.33%346.67%-195.79%-81.35%30.48%2.08%3.04%-109.57%-209.66%93.54%

Astec Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:4%
5 Years:-6%
3 Years:-17%
TTM:5%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
TTM:-63%
Stock Price CAGR
10 Years:14%
5 Years:-7%
3 Years:-23%
1 Year:-29%
Return on Equity
10 Years:6%
5 Years:0%
3 Years:-14%
Last Year:-45%

Last Updated: September 4, 2025, 11:55 pm

Balance Sheet

Last Updated: December 4, 2025, 12:59 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 19191920202020202020202022
Reserves 9511699119150183227290377400350215392
Borrowings 839312712712517699187279341494555367
Other Liabilities 8813385691198322618122121911292102
Total Liabilities 284362330334413461572678897979975881883
Fixed Assets 13213395103115167194213340318386499500
CWIP 61220842192411623127165210
Investments 0000000000000
Other Assets 146216215223256275354349534534424361383
Total Assets 284362330334413461572678897979975881883

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 157-13196515168-8247510-8
Cash from Investing Activity + -19-19-17-18-49-52-74-73-104-113-135-15
Cash from Financing Activity + 31231-1-1837-9581803812524
Net Cash Flow -1-021-3-0000-000
Free Cash Flow -4-13-39-115-37123-111-80-42-125-24
CFO/OP 47%19%-24%41%116%41%219%13%34%104%-211%20%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-48.00-39.00-95.00-64.00-56.00-100.00-14.00-75.00-125.00-264.00-500.00-621.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 9114212613512210311212314890135141
Inventory Days 192147177133122121131113176268224196
Days Payable 11417916911615583218137179161102100
Cash Conversion Cycle 1681091341528914225100145197256237
Working Capital Days 2319-281-8-28412-17-1-26
ROCE %11%20%12%20%22%20%20%22%22%8%-4%-13%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 66.76%66.76%66.75%66.75%66.75%66.75%66.74%66.74%70.87%70.87%72.42%71.97%
FIIs 2.29%1.95%1.33%1.28%1.25%1.03%0.53%1.20%0.25%0.02%0.00%0.04%
DIIs 10.58%10.15%10.16%9.74%7.88%3.37%4.50%5.40%4.34%4.26%4.01%3.17%
Public 20.37%21.13%21.74%22.22%24.12%28.85%28.20%26.64%24.53%24.84%23.57%24.82%
No. of Shareholders 17,80918,70318,72219,24419,84819,95519,72719,05718,68918,54918,27622,293

Shareholding Pattern Chart

No. of Shareholders

Astec Lifesciences Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Nippon India Small Cap Fund 526,867 0.05 30.29468,5892025-12-08 04:51:5812.44%
ICICI Prudential Commodities Fund 128,411 0.21 7.38112,3602025-12-08 04:51:5814.29%
ICICI Prudential MidCap Fund 18,107 0.01 1.0415,8442025-12-08 00:51:5414.28%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) -68.71-23.9313.0445.8733.23
Diluted EPS (Rs.) -68.71-23.9313.0445.8533.21
Cash EPS (Rs.) -46.40-5.4230.2263.3946.32
Book Value[Excl.RevalReserv]/Share (Rs.) 119.70188.44214.00202.40157.91
Book Value[Incl.RevalReserv]/Share (Rs.) 119.70188.44214.00202.40157.91
Revenue From Operations / Share (Rs.) 194.43233.66320.40345.23283.28
PBDIT / Share (Rs.) -30.89-0.1345.5683.9661.00
PBIT / Share (Rs.) -53.18-18.6228.3966.4347.90
PBT / Share (Rs.) -71.89-31.4917.8261.8145.47
Net Profit / Share (Rs.) -68.69-23.9113.0545.8633.22
NP After MI And SOA / Share (Rs.) -68.71-23.9313.0445.8533.21
PBDIT Margin (%) -15.88-0.0514.2124.3121.53
PBIT Margin (%) -27.35-7.978.8619.2416.90
PBT Margin (%) -36.97-13.475.5617.9016.05
Net Profit Margin (%) -35.32-10.234.0713.2811.72
NP After MI And SOA Margin (%) -35.33-10.244.0613.2811.72
Return on Networth / Equity (%) -57.40-12.706.0922.6621.03
Return on Capital Employeed (%) -20.22-6.3212.2832.0526.40
Return On Assets (%) -15.28-4.812.6110.029.60
Long Term Debt / Equity (X) 1.190.530.020.000.12
Total Debt / Equity (X) 2.361.340.810.700.60
Asset Turnover Ratio (%) 0.410.460.660.850.88
Current Ratio (X) 0.931.000.941.051.03
Quick Ratio (X) 0.490.510.380.670.69
Inventory Turnover Ratio (X) 2.141.301.913.043.03
Dividend Payout Ratio (NP) (%) 0.00-6.2611.503.264.51
Dividend Payout Ratio (CP) (%) 0.00-27.544.962.363.23
Earning Retention Ratio (%) 0.00106.2688.5096.7495.49
Cash Earning Retention Ratio (%) 0.00127.5495.0497.6496.77
Interest Coverage Ratio (X) -1.65-0.014.3118.1725.15
Interest Coverage Ratio (Post Tax) (X) -2.67-0.852.2410.9214.69
Enterprise Value (Cr.) 1875.492574.293049.603711.792144.94
EV / Net Operating Revenue (X) 4.925.624.855.493.87
EV / EBITDA (X) -30.96-9580.5334.1422.5617.95
MarketCap / Net Operating Revenue (X) 3.474.554.315.083.53
Retention Ratios (%) 0.00106.2688.4996.7395.48
Price / BV (X) 5.645.646.468.666.34
Price / Net Operating Revenue (X) 3.474.554.315.083.53
EarningsYield -0.10-0.020.010.020.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Astec Lifesciences Ltd. is a Public Limited Listed company incorporated on 25/01/1994 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1994PLC076236 and registration number is 076236. Currently Company is involved in the business activities of Manufacture of insecticides, rodenticides, fungicides, herbicides. Company's Total Operating Revenue is Rs. 381.30 Cr. and Equity Capital is Rs. 19.61 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Agro Chemicals/PesticidesGodrej One, 3rd Floor, Pirojshanagar, Mumbai Maharashtra 400079Contact not found
Management
NamePosition Held
Mr. Nadir B GodrejChairman
Mr. Burjis N GodrejManaging Director
Mr. Balram Singh YadavNon Executive Director
Mr. Ashok V HiremathNon Executive Director
Dr. Ganapati YadavIndependent Director
Mr. R R GovindanIndependent Director
Mr. Nandkumar DhekneIndependent Director
Ms. Anjali GupteIndependent Director

FAQ

What is the intrinsic value of Astec Lifesciences Ltd and is it undervalued?

As of 14 April 2026, Astec Lifesciences Ltd's intrinsic value is ₹408.16, which is 26.85% lower than the current market price of ₹558.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (45.3 %), book value (₹186), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Astec Lifesciences Ltd?

Astec Lifesciences Ltd is trading at ₹558.00 as of 14 April 2026, with a FY2026-2027 high of ₹991 and low of ₹512. The stock is currently near its 52-week low. Market cap stands at ₹1,243 Cr..

How does Astec Lifesciences Ltd's P/E ratio compare to its industry?

Astec Lifesciences Ltd has a P/E ratio of , which is below the industry average of 25.27. This is broadly in line with or below the industry average.

Is Astec Lifesciences Ltd financially healthy?

Key indicators for Astec Lifesciences Ltd: ROCE of 12.9 % is moderate; ROE of 45.3 % shows strong shareholder returns. Dividend yield is 0.00 %.

Is Astec Lifesciences Ltd profitable and how is the profit trend?

Astec Lifesciences Ltd reported a net profit of ₹-135 Cr in Mar 2025 on revenue of ₹381 Cr. Compared to ₹90 Cr in Mar 2022, the net profit shows a declining trend.

Does Astec Lifesciences Ltd pay dividends?

Astec Lifesciences Ltd has a dividend yield of 0.00 % at the current price of ₹558.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Astec Lifesciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports